InterMune Inc. (ITMN)

[onemodolar]

Earning C.C. on this Wed. 8/6

I believe ITMN will advance higher this upcoming week and reach new highs surpassing current TP's.

EU and Canadian roll out can gain the traction from recent trial result. They may increase the full year guidelines.

The Balance sheet will look better than ever with no debt and decreased overall expenses.

ITMN is capable of "Go it Alone" with previous marketing experience for Actimmune and Esbriet outside U.S..

So nice and lean pipeline as "fibrosis specialty co." It can not come any better than this as s "take over candidate".

Imagine "off label use" will be very common in all kind of ILD at any level of severity.

All IMO,
GLTA